This market will resolve to "Yes" if the President of the United States, any member of the Cabinet of the United States, any member of the Joint Chiefs of Staff, or any US federal agency definitively states that extraterrestrial life or technology exists by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the government of the United States, however a consensus of credible reporting will also be used.

December 31

This market will resolve to "Yes" if the President of the United States, any member of the Cabinet of the United States, any member of the Joint Chiefs of Staff, or any US federal agency definitively states that extraterrestrial life or technology exists by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the government of the United States, however a consensus of credible reporting will also be used.

September 30

This market will resolve to "Yes" if the President of the United States, any member of the Cabinet of the United States, any member of the Joint Chiefs of Staff, or any US federal agency definitively states that extraterrestrial life or technology exists by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the government of the United States, however a consensus of credible reporting will also be used.

June 30

Will the US confirm that aliens exist by...?

This market will resolve based on SpaceX's market capitalization at the closing price on its first day of trading.

If no SpaceX IPO occurs by December 31, 2027, 11:59 PM ET, the market will resolve to "No IPO before 2028".

Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.

If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.

Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.

In the event of an interruption in the course of the normal trading session on SpaceX’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.

2.0T+

1.8T–2.0T

1.6T–1.8T

SpaceX IPO Closing Market Cap (Lower Strikes)

This market will resolve according to the value reported by the Global Land-Ocean Temperature Index for May 2026 when it is released.

An anomaly within a named bracket for May 2026 is necessary and sufficient to resolve this market immediately once the data becomes available, regardless of whether the figure for May 2026 is later revised.

The primary resolution source for this market will be the figure found in the table titled "GLOBAL Land-Ocean Temperature Index in 0.01 degrees Celsius" under the column "May" in the row "2026" (https://data.giss.nasa.gov/gistemp/tabledata_v4/GLB.Ts+dSST.txt).

If NASA’s “Global Temperature Index” is rendered permanently unavailable, other information from NASA may be used.
If no information for May 2026 is provided by NASA by July 1, 2026, 11:59 PM ET, this market will resolve to the lowest range bracket.

1.10–1.14ºC

1.15–1.19ºC

<1.10ºC

Temperature Increase

May 2026 Temperature Increase (ºC)

This market will resolve according to the numerical rank of how hot 2026 is when compared against all other years for which the Global Land-Ocean Temperature Index has data.

Years will be ranked in descending order, starting with the hottest as number 1, the second hottest as number 2, etc.

If 2026 ties with any other year, it will resolve according to the place the year it ties with occupies.

This market will resolve immediately once the specified data becomes available, regardless of whether the figure for the relevant years is later revised.

The primary resolution source for this market will be the figure found in the table titled "Land-Ocean Temperature Index (C)" under the column "No_Smoothing" in the row "2026" (https://data.giss.nasa.gov/gistemp/graphs/graph_data/Global_Mean_Estimates_based_on_Land_and_Ocean_Data/graph.txt). If NASA's "Global Temperature Index" is rendered permanently unavailable, other information from NASA may be used. If no information for 2026 is provided by NASA by March 1, 2027, 11:59 PM ET, this market will resolve based on a consensus of credible reporting.

6 or lower

Where will 2026 rank among the hottest years on record?

This market will resolve based on the data for the Global Land-Ocean Temperature Index for June 2026 versus the data points available for all other Junes on record. 

Note: If June 2026 is tied for first, second, or third hottest with another year, it will qualify for the bracket it ties with.

The primary resolution source for this market will be the figures found in the table titled "GLOBAL Land-Ocean Temperature Index in 0.01 degrees Celsius" under the column "Jun" (https://data.giss.nasa.gov/gistemp/tabledata_v4/GLB.Ts+dSST.txt). If NASA's "Global Temperature Index" is rendered permanently unavailable, other information from NASA may be used.
If no information for June 2026 is provided by NASA by July 31, 2026, 11:59 PM ET, a consensus of credible sources will be used to resolve this market.

2nd hottest

1st hottest

4th or lower

Hottest Month

2026 June 1st, 2nd, 3rd hottest on record?

This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026, according to the CDC case counter by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Measles (Rubeola) counter 'Total Cases' in 2026 (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.

2150

2200

2300

measles

Measles cases in U.S. by June 30?

This market will resolve according to the number of SpaceX launches between June 1, 2026, 12:00 AM ET and June 30, 2026, 11:59 PM ET.

The resolution source for this market will be https://www.spacex.com/launches. 

Monthly SpaceX launches

How many SpaceX launches in June 2026?

This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.

↑3k

↑4k

↑5k

Measles cases in U.S. in 2026?

This market will resolve according to the total number of earthquakes with a magnitude of 7.0 or higher that occur anywhere on Earth between December 4, 2025, 12:00 PM ET, and June 30, 2026, 11:59 PM ET.

The resolution source for this market is the United States Geological Survey (USGS) Earthquake Hazards Program (https://earthquake.usgs.gov/earthquakes/browse/significant.php#sigdef).

If an earthquake of substantial size has occurred within this market's timeframe but not yet appeared on the resolution source, this market may remain open until July 7, 2026, 11:59 PM ET, or until the earthquake in question otherwise appears on the resolution source. If such an earthquake has not appeared on the resolution source by that date, another credible resolution source will be used.

How many 7.0 or above earthquakes by June 30?

This market will resolve to "Yes" if the World Health Organization (WHO) declares any disease a pandemic between January 1, 2026 and December 31, 2026 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source will be official announcements from the World Health Organization.

New Pandemic

New pandemic in 2026?

As of market creation, the FDA's expected decision date for the specified application is June 18, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for GSK & Spero Therapeutics's Tebipenem HBr as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis by July 2, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA Approval

FDA approves GSK & Spero Therapeutics' Tebipenem HBr?

As of market creation, the FDA's expected decision date for the specified application is June 29, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Unicycive's Oxylanthanum carbonate as a treatment for hyperphosphatemia in CKD patients on dialysis by July 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Unicycive's Oxylanthanum carbonate?

This market will resolve based on the data for the Global Land-Ocean Temperature Index for May 2026 versus the data points available for all other Mays on record. 

Note: If May 2026 is tied for first, second, or third hottest with another year, it will qualify for the bracket it ties with.

The primary resolution source for this market will be the figures found in the table titled "GLOBAL Land-Ocean Temperature Index in 0.01 degrees Celsius" under the column "May" (https://data.giss.nasa.gov/gistemp/tabledata_v4/GLB.Ts+dSST.txt). If NASA's "Global Temperature Index" is rendered permanently unavailable, other information from NASA may be used.
If no information for May 2026 is provided by NASA by June 30, 2026, 11:59 PM ET, a consensus of credible sources will be used to resolve this market.

3rd hottest

2026 May 1st, 2nd, 3rd hottest on record?

This market will resolve to the company that achieves the highest market capitalization in U.S. dollars based on the official closing price on its first trading day in 2026.

This market will resolve to a company that completes an Initial Public Offering (IPO) between January 1 and December 31, 2026, 11:59 PM ET.

Market capitalization is defined as the total number of outstanding shares multiplied by the closing share price on the first trading day.

If two or more companies have exactly equal highest closing market capitalizations, this market will resolve to the company whose listed name comes first alphabetically.

Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.

In case the respective company's primary exchange’s official listing page does not report in U.S. dollars, it will be converted to U.S. dollars using the U.S. Federal Reserve Board’s H.10 foreign exchange reference rate for the relevant currency pair on the company’s first trading day (https://www.federalreserve.gov/releases/h10/). If no such rate is available for the relevant trading day, the most recent previously published rate will be used. If the relevant currency is not listed, another credible exchange rate source will be used.

A listed company may resolve to "No" as soon as it becomes unable to complete an IPO, including due to acquisition, merger, or absorption by an entity that is already publicly traded.

In the event of an interruption in the course of the normal trading session on the respective companies’ first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.

SpaceX

Anthropic

OpenAI

Largest IPO by market cap in 2026?

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Kiniksa & Regeneron's Arcalyst related to the technology transfer to Samsung Biologics as a replacement CDMO by July 3, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Arcalyst technology transfer?

This market will resolve according to the total number of earthquakes with a magnitude of 5.5 or higher that occur anywhere on Earth between June 1, 2026, 12:00 AM ET, and June 7, 2026, 11:59 PM ET.

The resolution source for this market is the United States Geological Survey (USGS) Earthquake Hazards Program, with the minimum magnitude set to 5.5 and the date parameters set to the relevant dates for this market's timeframe (https://earthquake.usgs.gov/earthquakes/search/).

If an earthquake of substantial size has occurred within this market's timeframe but not yet appeared on the resolution source, this market may remain open until June 30, 2026, 11:59 PM ET, or until the earthquake in question otherwise appears on the resolution source. If such an earthquake has not appeared on the resolution source by that date, another credible resolution source will be used.

This market may not resolve until the timeframe of this market has concluded. If a qualifying earthquake has been recorded on the final day, this market may remain open for 24 hours to allow for revisions to the recorded magnitude. After 24 hours, this market will resolve according to the latest provided data.

≤5

5.5 Earthquake

How many 5.5 or above earthquakes June 1 - June 7?

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Viridian Therapeutics' Veligrotug?

This market will resolve according to the total number of earthquakes with a magnitude of 6.5 or higher that occur anywhere on Earth between June 1, 2026, 12:00 AM ET, and June 7, 2026, 11:59 PM ET.

The resolution source for this market is the United States Geological Survey (USGS) Earthquake Hazards Program (https://earthquake.usgs.gov/earthquakes/browse/significant.php#sigdef).

If an earthquake of substantial size has occurred within this market's timeframe but not yet appeared on the resolution source, this market may remain open until June 30, 2026, 11:59 PM ET, or until the earthquake in question otherwise appears on the resolution source. If such an earthquake has not appeared on the resolution source by that date, another credible resolution source will be used.

This market may not resolve until the timeframe of this market has concluded. If a qualifying earthquake has been recorded on the final day, this market may remain open for 24 hours to allow for revisions to the recorded magnitude. After 24 hours, this market will resolve according to the latest provided data.

6.5 Earthquake Weekly

How many 6.5 or above earthquakes June 1 - June 7?

This market will resolve according to the cumulative influenza-associated hospitalization rate per 100,000 population for the United States, as reported for the specified week.

If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.

The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.

Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.

85–90

90–95

100+

Flu Hospitalization Rate Week

Flu Hospitalization Rate Week 22, 2026?

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Ionis' Olezarsen?

This market will resolve to "Yes" if any human-crewed mission lands on the moon between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

A touchdown of the spacecraft with humans aboard will be sufficient to resolve this market to "Yes", regardless of technical complications.

The resolution source will be a consensus of credible reporting.

Human moon landing in 2026?

As of market creation, the FDA's expected decision date for the specified application is June 29, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Arcutis's Zoryve cream as a treatment for plaque psoriasis in children aged 2 to 5 by July 13, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Arcutis' Zoryve cream?

If Rocket Lab’s Neutron rocket successfully launches from its launch pad by December 31, 2026, 11:59 PM ET, this market will resolve to “Yes”. Otherwise, this market will resolve to “No.”

The outcome of any launch will be corroborated by examining official video provided by Rocket Lab (https://www.youtube.com/@RocketLabCorp), as well as secondary video feeds and/or written reports if necessary.

Any subsequent anomaly (e.g., explosion or failed ascent) after the initial liftoff will have no bearing on the outcome. Any name change or rebranding of the Neutron vehicle will have no bearing on the market’s resolution.

Rocket Lab’s Neutron Rocket Launch by December 31?

This market will resolve to "SpaceX" if SpaceX (Space Exploration Technologies Corp.) completes an Initial Public Offering (IPO) before OpenAI completes an IPO by December 31, 2027, 11:59 PM ET, as confirmed by official company announcements and credible news sources. 

This market will resolve to "OpenAI" if OpenAI completes an Initial Public Offering (IPO) before SpaceX completes an IPO by December 31, 2027, 11:59 PM ET, as confirmed by official company announcements and credible news sources. 

This market will resolve 50-50 if:
- Neither SpaceX nor OpenAI completes an Initial Public Offering (IPO) by December 31, 2027, 11:59 PM ET;
- Both SpaceX and OpenAI complete an IPO on the same calendar date (ET); or
- By December 31, 2027, 11:59 PM ET, both companies become unable to complete an IPO, including due to acquisition, merger, or absorption by an entity that is already publicly traded.

The IPO refers to the first sale of stock by the listed company to the public on any recognized stock exchange.

The resolution source for this market is a consensus of credible reporting.

Science